The resolution of a dispute between Germany's health ministry and health care reimbursement authority has restarted the country's plan for expedited approval of medtech devices that show great promise but still lack evidence from clinical trials. The dispute between the two agencies centered on definitions of "success" and a payback scheme for industry applicants that has now been dropped.

Full Story:

Related Summaries